Can the Prevail programme for employees and managers improve workplace productivity, decrease sickness absence and reduce stigma due to common mental disorder?

Reducing stigma, decreasing sickness absence, and increasing workplace productivity due to mental health difficulties in a large government organization in the UK: A protocol for a randomised controlled trial (RCT) of a low-intensity psychological intervention and stigma reduction programme for common mental disorder (Prevail)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12040087

Enrollment

1040

Registered

2020-05-04

Start date

2019-10-01

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental health and well-being Mental and Behavioural Disorders

Interventions

A sample of 80 managers and their teams (approximate total of 960 employees) will be selected by the UK Driver and Vehicle Licensing Agency (DVLA) to be eligible to take part in the Prevail interventi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Employees of DVLA in divisions of Information Technology Services (ITS), Contact Centre (CC), Case work and Enforcement (CAEG), and Input Services Group (ISG).

Exclusion criteria

Exclusion criteria: Not selected to take part in the Prevail intervention programme

Design outcomes

Primary

Measure	Time frame
1. Attitudes to mental health assessed using the Stigma and Self-Stigma scale (SASS) at baseline (before delivery of the Prevail programme), 1-4 weeks after Prevail delivery and 12 months after Prevail delivery 2. Rates of absenteeism during the 12 months prior to Prevail and 12 months post-Prevail will be extracted from the organisation’s sickness absence records	—

Secondary

Measure	Time frame
1. Work performance assessed using the Health and Work Performance Questionnaire (HPQ). 2. Impairment in functioning due to a common mental disorder assessed using the Work and Social Adjustment Scale (WSAS) 3. Symptoms of general anxiety assessed using the General Anxiety Disorder Assessment (GAD-7) measures 4. Depression severity assessed using the Patient Health Questionnaire (PHQ-9) 5. Mental distress assessed using the Kessler Psychological Distress Scale (K6) 6. Quality of life assessed using the EQ-5D-5L questionnaire All secondary outcome measaures will be assesed at at baseline (before delivery of the Prevail programme), 1-4 weeks after Prevail delivery and 12 months after Prevail delivery.	—

Measure

Time frame

1. Work performance assessed using the Health and Work Performance Questionnaire (HPQ). 2. Impairment in functioning due to a common mental disorder assessed using the Work and Social Adjustment Scale (WSAS) 3. Symptoms of general anxiety assessed using the General Anxiety Disorder Assessment (GAD-7) measures 4. Depression severity assessed using the Patient Health Questionnaire (PHQ-9) 5. Mental distress assessed using the Kessler Psychological Distress Scale (K6) 6. Quality of life assessed using the EQ-5D-5L questionnaire All secondary outcome measaures will be assesed at at baseline (before delivery of the Prevail programme), 1-4 weeks after Prevail delivery and 12 months after Prevail delivery.

—

Countries

United Kingdom, Wales

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 27, 2026